Novo Nordisk's November Verdict: Oral Wegovy Demand and FDA Timelines Set the Terms

Novo Nordisk reports quarterly results on November 4 as analysts split on the stock, which has lost about a quarter of its value this year.

Novo Nordisk has spent the autumn doing what a company under pressure does: buying back its own stock, licensing molecules from abroad, and waiting on regulators. Whether any of it moves the needle now comes down to a single date — November 4, when the Danish drugmaker reports quarterly results.

The setup is uncomfortable. The shares have shed roughly a quarter of their value since the start of the year, with the stock last changing hands at EUR 33.45 on Monday, following a session that closed at EUR 33.15 on another reading of the tape. That decline frames the central question facing investors: have the losses run far enough to make the valuation attractive, or is caution still the wiser stance ahead of hard numbers?

JPMorgan Stays Neutral, Deutsche Bank Stays Negative

Analyst positioning reflects that split. JPMorgan reaffirmed a "Neutral" rating on Monday with a price target of DKK 275, pointing to expectations of solid quarterly figures and developments around the oral version of Wegovy. Deutsche Bank Research took a harsher line on September 29, keeping a "Sell" rating and a DKK 245 target after reviewing weekly prescription data, according to media reports. The German bank's caution stems from intensifying competition in metabolic therapies, where rival products are eroding market share.

Both camps agree on one thing: the oral franchise is the swing factor. As competition in weight-loss medicine heats up worldwide, the shift from regular injections to daily pills will determine whether Novo Nordisk defends its leading position. Early clinical evidence offers encouragement. Data from the OCTANE study showed adults with overweight or obesity who switched from injectable semaglutide or tirzepatide to oral semaglutide lost an average of 4.1% of body weight after three months. The trial also tracked adherence and patient satisfaction.

If Novo Nordisk can convert those therapeutic advantages into sustained prescription volumes, it locks in recurring revenue in its core business. Should demand for the oral variants fall short of analyst expectations, growth across the entire segment risks slowing.

Pipeline Data Build the Bull Case

The upside scenario rests on stretching the company's core molecules well beyond obesity treatment. Demonstrating additional clinical benefits in cardiometabolic conditions would expand the long-term patient pool considerably.

Two data sets support that ambition. In the STEP-UP study, 23 of 26 participants with elevated liver fat at baseline recorded liver fat content below 5% after treatment with pooled semaglutide. Separately, the Phase 3 REIMAGINE 5 trial showed the combination candidate CagriSema delivered an estimated average weight reduction of 12.4%, versus 9.1% for tirzepatide. In REDEFINE 9, CagriSema achieved a 21.0% reduction in body weight, while the placebo group showed minimal effect. Findings like these strengthen the scientific foundation for future label expansions.

Management is also buying optionality. Roughly a week ago, Novo Nordisk secured rights to the experimental obesity pill HRS-1596 from Jiangsu Hengrui Pharmaceuticals, covering development, manufacturing, and worldwide commercialization — excluding mainland China, Hong Kong, Macau, and Taiwan. The stock has slipped 1.9% since that announcement. In a separate move, the company agreed to payments of up to EUR 1.165 billion for use of the PharmaShell delivery system across as many as five development programs.

Buybacks Keep Running

Alongside the dealmaking, Novo Nordisk continues returning capital. On Monday the company disclosed further purchases under its existing buyback program, which carries a total volume of up to DKK 15 billion. One specific tranche permits repurchases of up to DKK 11,200,000,010.45, running through February 1, 2027. On September 28, the company reported buying back 1,205,000 B-shares during the prior trading week.

Denecimig Delay Clouds the Outlook

Set against those efforts are operational risks capable of stalling any recovery. The haemophilia A treatment Denecimig remains under FDA review, with the US regulator requiring remediation work at a manufacturing site. The agency has not provided a new timeline for a final decision. Novo Nordisk has stressed that the delay leaves its 2026 financial outlook untouched and that it is targeting a US market launch in the first half of 2027.

For investors, such holdups mean persistent uncertainty over revenue paths outside the main franchise. If production problems tie up additional resources or approval processes stall further, market skepticism could take hold.

What November 4 Will Settle

The battle lines are drawn. So long as demand for existing blockbusters holds and management shows progress on regulatory manufacturing requirements, the current valuation offers a workable base for stabilization. But if momentum in oral therapies falters, or further manufacturing shortfalls force the company to trim timelines for upcoming product launches, selling pressure is likely to return — and with it, a continuation of the medium-term downtrend as investors recalculate growth premiums for the group as a whole. The quarterly report on November 4, and management's accompanying commentary on oral Wegovy demand, will decide which way the stock heads into year-end.